DrugPatentWatch Database Preview
LONHALA MAGNAIR KIT Drug Profile
» See Plans and Pricing
Which patents cover Lonhala Magnair Kit, and when can generic versions of Lonhala Magnair Kit launch?
Lonhala Magnair Kit is a drug marketed by Sunovion Resp and is included in one NDA. There are twelve patents protecting this drug.
This drug has eighty-six patent family members in thirteen countries.
The generic ingredient in LONHALA MAGNAIR KIT is glycopyrrolate. There are seventeen drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
US ANDA Litigation and Generic Entry Outlook for Lonhala Magnair Kit
A generic version of LONHALA MAGNAIR KIT was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
Summary for LONHALA MAGNAIR KIT
International Patents: | 86 |
US Patents: | 12 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 2 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LONHALA MAGNAIR KIT at DailyMed |

Pharmacology for LONHALA MAGNAIR KIT
Drug Class | Anticholinergic |
Mechanism of Action | Cholinergic Antagonists |
US Patents and Regulatory Information for LONHALA MAGNAIR KIT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LONHALA MAGNAIR KIT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LONHALA MAGNAIR KIT
Country | Patent Number | Estimated Expiration |
---|---|---|
Austria | 453424 | Start Trial |
Japan | 6545684 | Start Trial |
Japan | 2009504287 | Start Trial |
Germany | 50312299 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for LONHALA MAGNAIR KIT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2435025 | 19C1040 | France | Start Trial | PRODUCT NAME: COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET DE FORMOTEROL (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); NAT. REGISTRATION NO/DATE: EU/1/18/1339 20181220; FIRST REGISTRATION: - EU/1/18/1339 20181220 |
2435025 | 2019C/532 | Belgium | Start Trial | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
2435025 | LUC00124 | Luxembourg | Start Trial | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |